Rezolute Awaits FDA Review of Ersodetug in Congenital HI
REDWOOD CITY, Calif. — September 9, 2026 Rezolute, Inc. provided an update on the U.S. Food and Drug Administration’s...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
REDWOOD CITY, Calif. — September 9, 2026 Rezolute, Inc. provided an update on the U.S. Food and Drug Administration’s...
REDWOOD CITY, Calif., May 01, 2026 Rezolute, Inc. has announced detailed results from its Phase 3 sunRIZE study evaluating...
